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Abstract
It has been well established that schizophrenia patients display impaired NMDA receptor (NMDAR) functions as well as
exacerbation of symptoms in response to NMDAR antagonists. Abnormal NMDAR signaling presumably contributes to
cognitive deficits which substantially contribute to functional disability in schizophrenia. Establishing a mouse genetic
model will help investigate molecular mechanisms of hypoglutmatergic neurotransmission in schizophrenia. Here, we
examined the responses of Sp4 hypomorphic mice to NMDAR antagonists in electroencephalography and various
behavioral paradigms. Sp4 hypomorphic mice, previously reported to have reduced NMDAR1 expression and LTP deficit in
hippocampal CA1, displayed increased sensitivity and prolonged responses to NMDAR antagonists. Molecular studies
demonstrated reduced expression of glutamic acid decarboxylase 67 (GAD67) in both cortex and hippocampus, consistent
with abnormal gamma oscillations in Sp4 hypomorphic mice. On the other hand, human SP4 gene was reported to be
deleted in schizophrenia. Several human genetic studies suggested the association of SP4 gene with schizophrenia and
other psychiatric disorders. Therefore, elucidation of the Sp4 molecular pathway in Sp4 hypomorphic mice may provide
novel insights to our understanding of abnormal NMDAR signaling in schizophrenia.
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Introduction
In 1959, Luby et al [1] first reported their studies of
phencyclidine (PCP, Sernyl) in both healthy people and schizo-
phrenia patients. While healthy people treated with PCP displayed
schizophrenia-like symptoms, the most striking finding was that
exacerbation of the symptoms experienced by patients persisted
for several weeks after PCP administration. The finding led to a
suggestion that the action of PCP touched upon the fundamental
aspect of the disease. Decades later, NMDA receptor genes were
cloned, and PCP was found to be a noncompetitive N-methyl-D-
aspartate receptor (NMDAR) antagonist [2,3]. Ketamine, a
weaker noncompetitive NMDAR antagonist than PCP, was later
used to replace PCP in human studies [4]. Prolonged ketamine
effects and exacerbation of symptoms were again observed in
schizophrenia patients [5–7]. Direct evidence of NMDAR’s
crucial role in the pathophysiology of schizophrenia came from
the findings that patients with anti-NMDA-receptor encephalitis
(anti-NMDAR1) developed schizophrenia-like symptoms includ-
ing memory deficits [8,9].
It has now been well established that schizophrenia patients
have impaired NMDAR-mediated neurotransmission as well as an
increased sensitivity and prolonged responses to NMDAR
antagonists. Decreased expression of NMDAR1 was reported in
postmortem brains of schizophrenia patients [10–12]. However,
both Nmdar1 hypomorphic mice and mice with Nmdar1 condition-
ally knocked out in GABAergic interneurons displayed reduced,
rather than increased, sensitivity to the effects of NMDAR
antagonists on locomotion [13–15]. Therefore, it is necessary to
establish a new mouse genetic model to mimicking both decreased
NMDAR1 expression and increased sensitivity to NMDAR
antagonists in schizophrenia.
Sp4, a member of the Sp1 family of transcription factors,
recognizes GC-rich sequences readily identified in the ‘‘CpG
islands’’ around the promoters of a variety of genes [16]. Sp4 gene
is expressed restrictively in neuronal cells [17,18], and important
for postnatal development of hippocampal dentate gyrus [19]. We
previously reported that Sp4 hypomorphic mice displayed several
putative endophenotypes for schizophrenia and other psychiatric
disorders [18–20]. Impaired NMDAR functions were indicated in
Sp4 hypomorphic mice with decreased expression of NMDAR1
proteins and LTP deficit [20]. Importantly, human SP4 gene was
found to be deleted in schizophrenia (International Schizophrenia
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Consortium, 2008) [20,21], and its expression was decreased in the
postmortem brains of bipolar patients [22]. Moreover, human SP4
gene single nucleotide polymorphisms (SNPs) were also reported to
associate with bipolar disorder, schizophrenia, and major depres-
sion [23–26]. Together, these data demonstrated Sp4 hypomor-
phic mice as a promising hypoglutamatergic model for schizo-
phrenia. In the present work, we report that Sp4 hypomorphic
mice also exhibit prolonged responses to NMDAR antagonists
germane to Luby’s striking findings in schizophrenia more than 50
years ago.
Results
F1 generation mice from two different mouse strains were
generated for behavioral, electrophysiological, and molecular
studies, as recommended by Banbury Conference on Genetic
Background in Mice [27]. A large cohort of F1 129S/Black Swiss
mice was generated to examine differential ketamine responses
between wildtype and Sp4 hypomorphic mice. Guided by previous
studies on ketamine-induced PPI disruption [28], three different
dosages of ketamine (60 mg/kg, 80 mg/kg, and 100 mg/kg) were
tested for PPI disruption in some of the heterozygous F1 mice
(data not shown). From the pilot study, a dosage of 80 mg/kg was
chosen for its effective PPI disruption without sedation, and the
heterozygous mice used in the pilot study were excluded for the
following ketamine studies. In PPI, neither sex effect
(F(1,58) = 0.38, n.s.) nor sex and ketamine interaction
(F(1,58) = 0.53, n.s.) was observed between wildtype, heterozygous,
and Sp4 hypomorphic mice. Therefore, both sexes were combined
for all subsequent analyses. A significant difference in PPI was
observed between wildtype, heterozygous, and Sp4 hypomorphic
mice (F(2,61) = 11.69, p,0.0001) (Figure 1A). Significant gene X
ketamine X prepulse intensity interaction was also observed
(F(4,122) = 4.93, p,0.001). Post-hoc analysis revealed that Sp4
hypomorphic mice displayed significantly lower PPI than wildtype
sibling mice treated with ketamine across all three prepulse levels.
No significant differences were observed in startle responses
between wildtype, heterozygous, and Sp4 hyomorphic mice,
although ketamine reduced startle across all groups (Figure S1).
To examine the time course of ketamine effects, the PPI session
was subdivided into the first and second blocks. Time block
analysis revealed a significant block X gene interaction
(F(2,61) = 3.18, p,0.05) (Figure 1B). In wildtype mice treated
with ketamine, a significant PPI recovery was observed in the
second block from the PPI of the first block. However, no PPI
recovery was observed in the second block in Sp4 hypomorphic
mice treated with ketamine, suggesting prolonged ketamine effects
in the mutant mice.
Differential ketamine responses were further examined in
another behavioral paradigm, video-track (VT) locomotion test.
A between-subjects design was used for the VT test without prior
habituation in locomotion chambers. A lower dosage of ketamine
(60 mg/kg) was used to better detect gene and drug interactions.
Neither sex effect nor sex and ketamine interaction was observed
in locomotor activities; therefore, both sexes were combined in
analysis. Between the two genotypes of mice, no significant
difference in the total distance traveled was found (F(1,40) = 1.25,
n.s.). However, there was a significant gene X time block
interaction (F(5,100) = 2.33, p,0.05), but a trend of gene effect
(F(1,20) = 3.63, p,0.1) in Sp4 hypomorphic mice injected with
saline vehicle. Post hoc analyses revealed significant less distance
traveled at the second (p,0.05), the third (p,0.05), and a trend at
the fourth (p,0.1) time blocks. Both wildtype and Sp4 hypomor-
phic mice displayed habituation in total distance traveled during
60 min recording (Figure 1C). Administration of ketamine at the
dosage of 60 mg/kg significantly increased the total distance
traveled in both wildtype and Sp4 hypomorphic mice
(F(1,40) = 37.37, p,0.0001). As expected, a significant gene X
ketamine interaction was observed (F(1,40) = 7.97, p,0.01). Post
hoc analysis revealed that Sp4 hypomorphic mice displayed
significantly more locomotion than wildtype sibling controls at
both block 5 (F(1,40) = 7.59, p,0.01) and block 6 (F(1,40) = 5.29,
p,0.05), confirming prolonged ketamine responses in the mutant
mice. The absence of ketamine-induced locomotion increase in the
wildtype mice at the first block may be masked by hyperlocomo-
tion because mice were not previously habituated in the chambers.
To rule out the possibility that ketamine concentrations may be
different in the brains of wildtype and Sp4 hypomorphic mice, a
new cohort of mice were generated and injected with the same
dosage of ketamine. The concentrations of ketamine and its
metabolite norketamine were measured 15 minutes later after
injection. Cortical concentrations of either ketamine or norketa-
mine were not different between wildtype and Sp4 hypomorphic
mice (Figure 1D). Therefore, we concluded that the prolonged
ketamine responses of Sp4 hypomorphic mice resulted from the
extended neural responses to the same concentration of ketamine.
It was reported that ketamine could also bind to dopamine and
serotonin receptors [29], although with low affinities. To examine
whether the differential ketamine responses were mediated
through NMDAR, not ‘‘off-target’’ low affinity binding receptors,
a competitive NMDAR antagonist, SDZ 220–581 [30], was used
in locomotion tests in a third mouse test cohort (Figure 1E). There
was a trend (F(1,20) = 3.95, p,0.1) of lower locomotion in Sp4
hypomorphic mice than wildtype sibling mice injected with saline.
However, injection of SDZ 220–581, while increasing locomotion
during the first two 10-min blocks in wildtype mice, generated
prolonged responses in Sp4 hypomorphic mice with a significant
gene and SDZ drug interaction (F(1,20) = 21.19, p,0.001). Post hoc
analysis revealed that Sp4 hypomorphic mice displayed signifi-
cantly more locomotion than wildtype sibling controls at all blocks
except the first one. Ketamine and SDZ 220–581 are structurally
different chemicals binding to different sites of NMDAR. It is
unlikely that both chemicals have common ‘‘off-target’’ bindings
to generate the same behavioral phenotypes. Therefore, we
consider that alteration of NMDAR signaling in Sp4 hypomorphic
mice was responsible for the exaggerated responses to both
ketamine and SDZ 220–581.
To investigate the differential ketamine responses at a neural
circuit level, we generated a fourth mouse test cohort and
conducted electroencephalography (EEG) and simultaneous loco-
motion recording (Figure 2A). We further decreased the ketamine
dosage to 50 mg/kg to explore low limit of effective dosages, and
examined ketamine responses after mouse habituation in cham-
bers. Power spectral density was measured during one hour
recording of individual wildtype and Sp4 hypomorphic mouse. Sp4
hypomorphic mice displayed a trend of lower baseline power
(p,0.1) in gamma oscillations (.30 Hz) with no difference in low
frequency oscillations (,30 Hz) (Figure 2B). Injection of saline
vehicle did not cause any changes of baseline oscillations
(Figure 2C). However, injection of ketamine significantly altered
the oscillations across all frequencies in both wildtype and Sp4
hypomorphic mice. Increase of power in low gamma (30–80 Hz)
frequency range was induced by ketamine injection in both
genotypes. Interestingly, a small ‘‘peak’’ of power spectrum was
observed around 130 Hz in Sp4 hypomorphic mice injected with
ketamine. Further temporal analysis of power spectrogram
illustrated a narrow band of high frequency oscillations (ranging
from 130 to 160 Hz), a high gamma band induced by ketamine in
Ketamine Responses in Sp4 Mice
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all Sp4 hypomorphic mice, but none of wildtype mice (Figure 2D).
A time-course of ketamine-induced EEG power gain was
examined across all frequencies of oscillations (Figure 3A).
Administration of ketamine significantly increased low frequency
oscillations in both theta (4–8 Hz) and alpha (8–12 Hz) bands in
wildtype mice during the first ten minutes. However, no gain of
EEG power was observed in Sp4 hypomorphic mice injected with
ketamine. EEG powers of both theta and alpha bands gradually
decreased later after the first 10-min block in both genotypes. Beta
power (13–30 Hz) was not affected by ketamine injection, and no
difference was found between the two genotypes. In low gamma
(30–80 Hz) range, ketamine appeared to have prolonged effects in
Sp4 hypomorphic mice to generate a significant higher power at
40–50 minutes block. In contrast to low frequency oscillations,
administration of ketamine generated significantly higher powers
in high gamma (80–150 Hz) bands in Sp4 hypomorphic mice than
Figure 1. Increased sensitivity and prolonged responses to NMDAR antagonists. (A) There was a significant reduction of PPI in Sp4
hypomorphic mice (n = 21) in comparison with both wildtype (n = 24) and heterozygous mice (n = 19) (## p,0.01). $: significantly lower PPI in
heterozygous (p,0.05) than in wildtype mice treated with ketamine with 69 dB prepulses. Asterisks (*): significantly lower PPI in Sp4 hypomorphic (*
p,0.05; ** p,0.01) than in wildtype mice treated with ketamine. (B) PPI session was divided into two time blocks. Significant PPI recovery was
observed during the second block (B2) in wildtype mice, but not Sp4 hypomorphic mice, treated with ketamine. * p,0.05. (C) In video-track test, no
significant difference between wildtype and Sp4 hypomorphic mice treated with saline vehicle. Ketamine significantly increased total distance
traveled in both groups. Significantly more locomotion was observed in Sp4 hypomorphic mice than in wildtype mice treated with ketamine in the
last 20 minutes of recording (* p,0.05; ** p,0.01). (D) No difference was found in the concentrations of either ketamine or norketamine in the cortex
of wildtype (n = 5) and Sp4 hypomorphic (n = 5) mice. (E) In BPM locomotion tests, there was a trend of lower locomotion in Sp4 hypomorphic mice
injected with saline vehicle. Administration of SDZ 220–581 increased locomotion in both genotypes, but significant more locomotion was observed
in Sp4 hypomorphic mice (n = 9) than in wildtype mice (n = 13), particularly at later blocks (* p,0.05; ** p,0.01).
doi:10.1371/journal.pone.0066327.g001
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in wildtype sibling mice. After collapsing the data of the entire 50-
minute recording sessions, significantly more reduction of theta
oscillations and more increase of high gamma oscillations were
induced by ketamine in Sp4 hypomorphic mice than in wildtype
sibling mice (Figure 3B). During EEG recording, mouse locomo-
tion was also recorded (Figure 4A). Mice were habituated one hour
in the EEG recording chamber before injection of saline vehicle.
There was no difference in total distance traveled between the two
genotypes after saline injection (B1–B5). Injection of ketamine
significantly increased mouse locomotion in both genotypes. As
expected, Sp4 hypomorphic mice traveled significant more
distance than wildtype controls in the last 10-min block (B10).
Therefore, Sp4 hypomorphic mice displayed prolonged ketamine
responses in both recording and VT chambers at different dosages
of ketamine with or without prior habituation. In addition to
locomotor activities, Sp4 hypomorphic mice also displayed
different moving patterns (Figure 4B). After ketamine injection,
all 8 Sp4 hypomorphic mice displayed extensive thigmotaxis
moving, while most wildtype mice (7 out of 8) displayed random
hyperlocomotion. The moving patterns were consistent with our
previous finding that Sp4 hypomorphic mice spent less time in the
center of open field (Figure 4C) [18].
Cortical GABAergic inhibitory interneurons were reported to
be major targets of NMDAR antagonists [31,32], and the activities
of the interneurons generated gamma oscillations [33]. The
findings of both altered ketamine responses and decreased baseline
gamma oscillations in Sp4 hypomorphic mice prompted us to
examine whether the mutant mice had abnormal cortical
GABAergic inhibitory interneurons, particularly parvalbumin
positive interneurons [33]. We conducted immunohistochemical
staining of parvalbumin in the brains of both Sp4 hypomorphic
and wildtype mice [34] (Figure 5A). The number of positive
cortical parvalbumin interneurons was counted in different
cortical regions. No difference was found in either the number
of the interneurons or the staining intensity of parvalbumin
between the two genotypes (data not shown). We next examined
the expression of GAD67 proteins, a key enzyme in the synthesis
of GABA neurotransmitter, in GABAergic inhibitory interneurons
using immunohistochemical staining. Expression of GAD67
proteins was significantly reduced in both hippocampus and
cortex of Sp4 hypomorphic mice in comparison with those of
wildtype control mice (Figure 5A, 5B). Western blot analysis
confirmed the decrease of GAD67 expression in the hippocampus
and cortex of Sp4 hypomorphic mice (Figure 5C, 5D).
Discussion
Our previous studies demonstrated that Sp4 hypomorphic mice
displayed reduced expression of NMDAR1 and LTP deficit [20].
Here, we report that Sp4 hypomorphic mice also exhibit prolonged
and exaggerated responses in various behavioral paradigms to
both noncompetitive (ketamine) and competitive (SDZ 220–581)
NMDAR antagonists. Our studies suggested that alteration of
NMDAR signaling in Sp4 hypomorphic mice were responsible for
the differential ketamine responses. However, it remains to be
investigated how NMDA neurotransmission is altered in Sp4
hypomorphic mice. More electrophysiological studies are needed
to understand the underlying molecular mechanisms in future.
The present study concluded that Sp4 hypomorphic mice present
as a novel hypoglutamatergic genetic model to mimicking reduced
NMDAR1 expression and increased sensitivity to NMDAR
antagonists in schizophrenia.
An important question raised from our studies was how Sp4
hypomorphic and Nmdar1 hypomorphic mice displayed opposite
responses to NMDAR antagonists, considering that both had
reduced NMDAR1 expression [13,20]. There are some differenc-
es between the two mutant mice. First, reduction of NMDAR1
was more subtle in Sp4 hypomorphic mice than in Nmdar1
hypomorphic mice. Second, NMDAR1 is not the only down-
stream gene affected by Sp4 expression. Abnormal expression of
other Sp4 downstream genes may also contribute to their
differential responses. In our studies, we found down-regulation
of GAD67 proteins, a rate-limiting enzyme in GABA synthesis, in
Sp4 hypomorphic mice. Cortical GABAergic inhibitory interneu-
rons were proposed to be the primary targets of NMDAR
antagonists [31,32]. Conceivably, reduced NMDAR functions in
the GABAergic inhibitory interneurons of Sp4 hypomorphic mice
could alter ketamine responses in conjunction with decreased
GAD67 expression. However, it was reported that conditional
knockout of NMDAR1 in GABAergic inhibitory interneurons
generated similar phenotypes to Nmdar1 hypomorphic mice,
reduced sensitivity to NMDAR antagonists [14,15]. In these
Nmdar1 conditional knockout mice, expression of GAD67 was also
decreased in GABAergic inhibitory interneurons. These data
suggested that decreased expression of both NMDAR1 and
GAD67 in GABAergic inhibitory interneurons were not sufficient
to generate increased sensitivity to NMDAR antagonists. More-
over, recent studies suggested that excitatory pyramidal neurons
could be the primary targets of NMDAR antagonists [35].
Regardless of the primary target neurons of NMDAR antagonists,
however, it is possible that numerous downstream effectors of Sp4
molecular pathway in different types of neuronal cells may interact
to contribute to increased sensitivity and prolonged responses to
ketamine in Sp4 hypomorphic mice. Currently, we are conducting
genetic rescue experiments to reverse behavioral and molecular
abnormalities by breeding Sp4 hypomorphic mice with Emx1-Cre
and Dlx6a-Cre mouse strains to restore Sp4 expression in excitatory
and GABAergic inhibitory neurons respectively. The genetic
rescue experiments will evaluate the contribution of Sp4 molecular
pathway in each type of neuronal cells to specific mouse
phenotypes. After the dissection of behavioral phenotypes at the
cellular level, molecular studies can be conducted to investigate
underlying mechanisms in the right cellular context.
During EEG recording, we observed a band of high gamma
oscillations (130–160 Hz) induced by ketamine only in Sp4
hypomorphic mice. Similar narrow-band high gamma oscillations
have been reported to be induced in rodents injected with
increasing dosages of ketamine [36,37]. In our current studies, the
ketamine dosage used was not sufficient to induce high gamma
oscillations in wildtype mice, but adequate to do so in Sp4
hypomorphic mice, likely due to their increased sensitivity. There
was no difference in locomotion between the two genotypes during
the first three 10-min time blocks, ruling out the association of high
gamma oscillations with locomotion. It will be interesting to know
whether high gamma oscillations are associated with thigmotaxis
moving pattern in Sp4 hypomorphic mice, since high gamma
oscillation was suggested to associate with psychotic symptoms
[37]. Several different mechanisms have been proposed for the
generation of the high gamma oscillation [38,39]. It is unknown
whether high gamma oscillations may be an intermediate
phenotype of the exaggerated ketamine responses or simply a
consequence of increased sensitivity of Sp4 hypomorphic mice to
ketamine.
Decreased expression of GAD67 proteins in cortical inhibi-
tory interneurons is one of the most consistent findings in
postmortem brains of schizophrenia patients [40–42]. It has
been suggested that GABAergic inhibitory interneurons and
excitatory pyramidal neurons were responsible for the genera-
Ketamine Responses in Sp4 Mice
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tion of gamma oscillations (.30 Hz) and lower frequency
oscillations, respectively [33]. In Sp4 hypomorphic mice,
reduced expression of GAD67 proteins might contribute to
the lower power of baseline gamma oscillations. Excessive
release of glutamate has been reported in microdialysis studies
of rodent brains after injection of NMDAR antagonists [43,44].
Conceivably, excessive glutamate could generate initial EEG
power gain (first ten-minute) of both theta and alpha oscillations
Figure 2. Abnormal gamma oscillations in Sp4 hypomorphic mice. (A) A diagram of positions of recording and reference electrodes for
epidural EEG recording. (B) A trend of lower EEG power of gamma oscillations (.30 Hz) was observed in Sp4 hypomorphic (n = 8) mice than wildtype
mice (n = 8). Solid lines represent population-averaged power spectra and shaded areas around the lines represent SEM. (C) Power spectrogram for
wildtype (left) and Sp4 hypomorphic (right) mice around the time of intraperitoneal injection of saline vehicle and ketamine (50 mg/kg). Power
spectra (colored curves) integrated during a 50-minute time window after vehicle and ketamine injections were plotted in comparison to baseline
spectrum (gray curve). (D) Illustrated data range from 10 minutes before and 50 minutes after the injection of saline and ketamine. Welch method
with a Hamming window was used to estimate power spectra of 10 s, non-overlapping time bins. Black windows immediately before injections
indicate a lack of data due to injection. Increase of power in low gamma (30–80 Hz) frequency range was induced by ketamine, but not vehicle,
injection in both genotypes. Ketamine induced significant activity in high gamma (.80 Hz) frequency range only in the Sp4 hypomorphic mice.
doi:10.1371/journal.pone.0066327.g002
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via activation of excitatory pyramidal neurons in the wildtype
mice. However, we did not observe any initial gain of EEG
power in Sp4 hypomorphic mice. We speculated that both theta
and alpha low frequency oscillations could be dampened by
reduced NMDAR functions in the excitatory pyramidal neurons
in Sp4 hypomorphic mice. Administration of ketamine overall
decreased the power of low frequency theta oscillations and
increased the power of high frequency gamma oscillations,
which is consistent with previous reports [45]. However, such
effects were exaggerated in Sp4 hypomorphic mice.
Our studies suggested that Sp4 molecular pathway plays an
important role in the modulation of ketamine sensitivity. Recently,
ketamine has been demonstrated as one of most effective
antidepressants in the initial treatment of depression [46].
Interestingly, human SP4 gene has been found to be one of the
leading candidate genes associated with major depression [24,25].
It is not uncommon to find the same susceptibility gene for
different psychiatric disorders, as exemplified by the DISC1
translocation in a Scottish schizophrenia family [47–49]. Human
SP4 gene was found to be deleted in schizophrenia, and its SNPs
have been reported to associate with bipolar, schizophrenia, and
major depression. Functional SNP variants in human SP4 gene
could affect SP4 expression to alter ketamine responses. Identifi-
cation of these SP4 SNPs may help predict ketamine efficacy in
treatment of depression.
Figure 3. Time-course of ketamine-induced EEG power gain in various frequency ranges. (A) For 5 frequency ranges, i.e. theta, alpha,
beta, low gamma and high gamma, EEG powers were analyzed in 10-minute bins subsequent to intraperitoneal injection of 50 mg/kg ketamine or
saline vehicle. Illustrated are means and SEMs of population data for wildtype (n = 8) and Sp4 hypomorphic (n = 8) mice. Significant results of 2-
sample 2-tail Z-tests are indicated by asterisks (* p,0.05; ** p,0.01). (B) Vehicle- and ketamine-induced gain of power from baseline in various
frequency bands for the whole dataset. Error bars represent SEM. Results of 2-sample 2-tail Z-tests were shown above and below the bar plots;
Bonferroni correction for multiple hypothesis testing was used to adjust significance level (p = 0.05). Asterisks represent statistical significance and
circles indicate no significance. A significant increase in high gamma, but not in low gamma, power was induced by ketamine versus by vehicle in Sp4
hypomorphic animals. In addition, a significant reduction in theta power was caused by ketamine only in Sp4 hypomorphic mice.
doi:10.1371/journal.pone.0066327.g003
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Materials and Methods
Mouse Strains and Breeding
The Sp4 hypomorphic mice were generated as previously
described [18] and maintained as Sp4 heterozygous in 129S and
Black Swiss backgrounds respectively. The Sp4 129S strain has
been on pure 129S background since the germline transmission of
the targeted Sp4 allele, and backcrossed a few times with 129S
mice to prevent potential genetic drift in the last ten years. The Sp4
Black Swiss strain was backcrossed initially at least ten generations,
and continues to be backcrossed with Black Swiss mice every other
year to prevent potential genetic drift. The Sp4 test cohort was
generated by breeding the heterozygous Sp4 mice between the two
mouse strains. Therefore, all test mice were the F1 generation
mice with the same genetic background. Mice were housed in a
climate-controlled animal colony with a reversed day/night cycle.
Food (Harlan Teklab, Madison, WI) and water were available ad
libitum, except during behavioral testing. All behavioral testing
procedures were approved by the UCSD and Salk Animal Care
and Use Committee (permit number: A3033-01) prior to the onset
of the experiments. Mice were maintained in American Associ-
ation for Accreditation of Laboratory Animal Care approved
animal facilities at UCSD and local Veteran’s Administration
Hospital. These facilities meet all Federal and State requirements
for animal care.
Mouse Test Cohorts
Five different cohorts of F1 generation mice between 129S and
Black Swiss strains were generated for the studies. Each cohort
contained comparable numbers of males and females. The age
Figure 4. Simultaneous recording of mouse locomotion during EEG recording. (A) After one-hour habituation in EEG recording chamber,
mice were treated with saline. Both locomotion and EEG were simultaneously recorded for 50 min after saline injection. Additional 50 minute
recording was conducted after ketamine injection. Sp4 hypomorphic (n = 8) mice displayed prolonged ketamine effects in locomotion in comparison
with wildtype (n = 8) mice. (B) Differential locomotion patterns between wildtype (left) and Sp4 hypomorphic (right) mice injected with saline and
ketamine. (C) Thigmotaxis measured as the percentage of time the animal stayed in the central area of the recording chamber (gray square in B, an
area 5 cm away from the edge of the chamber). Asterisks indicate significant differences between the two genotypes and pound signs indicate
significant difference between saline vehicle and ketamine injections (2-sample Z-test); error bars represent SEM.
doi:10.1371/journal.pone.0066327.g004
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difference was less than two weeks between individual mice. All
mice were about 4–7 month old when used for studies.
Test cohort 1. The test cohort, consisting of 24 wildtype, 38
heterozygous, and 21 Sp4 hypomorphic (homozygous) mice, were
used to examine ketamine responses in prepulse inhibition (PPI)
and video-track tests. PPI tests were conducted at 4 months of age.
One month later, video-track locomotion tests were conducted.
Test cohort 2. The test cohort contained 5 wildtype and 5
Sp4 hypomorphic mice, and was used for studying ketamine
metabolism in vivo.
Test cohort 3. The test cohort contained 13 wildtype and 9
Sp4 hypomorphic mice, and was used for locomotion studies in the
behavioral pattern monitor (BPM) with SDZ 220–581 (10 mg/kg),
a competitive NMDAR antagonist.
Test cohort 4. The test cohort contained 8 wildtype and 8
Sp4 hypomorphic mice, and was used for simultaneous EEG
recording and locomotion studies with injection of ketamine
(50 mg/kg) or saline vehicle.
Test cohort 5. The test cohort contained 11 wildtype and 12
Sp4 hypomorphic mice. Seven wildtype and 7 Sp4 hypomorphic
mice were used for immunohistochemical analysis of parvalbumin
and GAD67 protein expression. Four wildtype and 5 Sp4
hypomorphic mice were used for Western blot analysis of
GAD67 protein expression.
Ketamine and SDZ220-581
Ketamine and SDZ 220–581 were dissolved in saline and
administered i.p. at a volume of 5 ml/kg immediately prior to the
start of the test session [28]. The doses of ketamine and SDZ 220–
581 were determined by pilot studies on some heterozygous mice
that were not included in further experiments. A within-subjects
crossover design was used for drug studies, with 1 week between
drug treatments.
Prepulse Inhibition
Startle reactivity and PPI were measured with startle
chambers (SR-LAB, San Diego Instruments, San Diego, CA)
Figure 5. Reduced expression of GAD67 in Sp4 hypomorphic mice. (A) Immunohistochemical staining of parvalbumin (PARV) and GAD67
proteins in both cortex and hippocampus of wildtype (n = 7) and Sp4 hypomorphic (n = 7) mice. To quantify the level of protein expression, the
sections were not counter-stained. The ‘‘white spots’’ in sections were nucleus of neuronal cells not stained by the antibodies. No difference was
found in parvalbumin staining, scale bar: 25 mm. Reduced expression of GAD67 was readily detected in the hippocampus (scale bar: 250 mm) and
cortex (scale bar: 60 mm) of Sp4 hypomorphic mice. (B) Quantification of GAD67 protein expression in immunohistochemical staining of different
brain regions (frontal cortex, somatosensory and motor cortex (SS-MO), visual cortex, hippocampal CA1, and hippocampal dentate gyrus (DG)) of
wildtype (n = 7) and Sp4 hypomorphic (n = 7) mice. Significant reduction of GAD67 staining was observed in all these regions. (C) Western blot
analysis confirmed decreased expression of GAD67 proteins in both hippocampus and cortex of Sp4 hypomorphic mice. Equal amount of proteins
were loaded, as shown by b-actin expression. (D) Quantification of GAD67 protein expression in Western blot. Significant reductions of GAD67
proteins were confirmed in Sp4 hypomorphic mice (n = 5) in comparison with wildtype sibling controls (n = 4). (* p,0.05; ** p,0.01).
doi:10.1371/journal.pone.0066327.g005
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as described [23]. All PPI test sessions consisted of startle trials
(PULSE-ALONE), prepulse trials (PREPULSE+PULSE), and
no-stimulus trials (NOSTIM). The PULSE-ALONE trial con-
sisted of a 40-ms 120-dB pulse of broad-band noise. PRE-
PULSE+PULSE trials consisted of a 20-ms noise prepulse,
80 ms delay, then a 40-ms 120-dB startle pulse (100 ms onset to
onset). The acoustic prepulse intensities were 69, 73, and 81 dB
(ie 4, 8, and 16 dB above the 65-dB background noise). The
NOSTIM trial consisted of background noise only. The test
session began and ended with five presentations of the PULSE-
ALONE trial; in between, each acoustic or NOSTIM trial type
was presented 10 times in a pseudo-random order. There was
an average of 15 s (range: 12–30 s) between trials. A
background noise level of 65 dB was presented for a 10-min
acclimation period and continued throughout the test session.
The amount of PPI was calculated as a percentage score for
each acoustic prepulse trial type: % PPI = 1002{[(startle
response for PREPULSE+PULSE)/(startle response for
PULSE-ALONE)]6100}. For PPI block analysis, the middle
PPI session was split into two blocks (B1 and B2). The PPI of
the first block was calculated with the first five PREPULSE+-
PULSE trials and six PULSE-ALONE trials; and the PPI of the
second block was calculated with the last five PREPULSE+-
PULSE trials and six PULSE-ALONE trials.
Locomotion Tests
Video-track test (VT). Locomotor activity was measured
using the Video-Tracker (VT) system with four adjacent white
plastic enclosures (41 X 41 X 34 cm3) at the floor level, which were
surrounded by an opaque plastic curtain. Mice were placed
separately into individual enclosures. Enclosures were wiped clean
between each test session, to remove residual odors. A video
camera, mounted 158 cm above the enclosures, generated the
signal for the Polytrack digitizer (San Diego Instruments). Signals
were processed to acquire the left-uppermost coordinate for each
of the four animals simultaneously; these data were then stored in
a PC computer for subsequent off-line processing and analysis.
The position of each animal (x, y) (in pixels) was sampled with a
frequency of 18.18 Hz, which was used to generate a coordinate
file (x, y, t) consisting of the x-location, y-location, and the duration
(time t) spent in that location. Each enclosure was further
subdivided for analysis by the software into nine equally sized
square regions. The spatio-temporal resolution of each recorded
event was 0.32 cm 6 0.32 cm 6 55 ms, corresponding to a
maximum speed of 25 cm/s.
Behavioral Pattern Monitor (BPM). Spontaneous behav-
ioral data were recorded using the BPM (San Diego Instruments,
San Diego, CA), as described previously [50,51]. In brief, a single
chamber consists of a 30.5661638-cm area, with a Plexiglas hole
board floor that was equipped with floor holes in the front, middle,
and rear parts of the floor and eight wall holes (three along each
side of the long walls and two holes in the front and back walls).
Mice were tested during the dark phase of their light cycle. During
testing, a white noise generator produced background noise at 65
dB. The measurement of transitions, center time, and spatial
coefficient of variation were based on the nine divided regions of
the chambers. The status of the photobeams was sampled every
0.1 sec. The session lasted 60 min. Raw data were transformed
into the location of the animal (in X–Y coordinates), whether
holepoking or rearing occurred (events), and the duration of each
event (time). The chambers were cleaned thoroughly between
testing sessions.
Analysis of Ketamine Metabolism in vivo
At 4 months of age, mice were i.p. injected with ketamine at a
dosage of 80 mg/kg. Because ketamine was known to be rapidly
metabolized in mice, individual mouse brains were dissected out
exactly 15 min later after ketamine injection following a brief
transcardial perfusion with 16PBS solution. The brains were then
quickly cooled down in ice-cold PBS solution. Mouse cortex was
further dissected out from 2 mm thickness coronal brain sections
(from Bregma 1.32 mm to 20.82 mm) cut with Brain Matrix, and
immediately homogenized and frozen in dry ice as recommended
by NMS Labs (Willow Grove, PA). The concentration of ketamine
and its metabolite norketamine was measured by NMS Labs.
EEG Recording and Analysis
Mice at the age of 6–7 months were implanted with a recording
device under isofluorane anesthesia. The implant device contained
stainless steel epidural EEG electrodes (hair-pinned contacts at a
depth of 0.5 mm from the surface of skull, using 1/8 mm diameter
stainless steel wires) and a nylon-coated stainless steel subcutane-
ous EMG electrode channeled through an electrode interface
board (EIB-8, Neuralynx). The recording electrode was positioned
on frontal cortex (1 mm rostral and 1 mm lateral from bregma)
and the reference electrode was placed 6 mm caudal from Bregma
on mid-sagittal line (above cerebellum). Craniotomies of 0.25 mm
diameter were drilled at stereotaxically positioned coordinates of
electrodes. Three jewelry screws and dental acrylic were used to fix
the implant onto the skull.
EEG recording sessions were conducted 2–7 days after surgery
during the light cycle. Before each recording session, the animal
was habituated to a transparent acrylic recording chamber 25 cm
by 25 cm in size. The implant was connected to a pre-amplifier
(HS-8, Neuralynx) with an interface cable to a slip-ring
commutator (SL-88-10, Dragonfly); EEG and EMG signals were
amplified and digitized (sampled at 1 kHz with 16-bit precision) by
the Digital Lynx system (Neuralynx) and stored on a hard drive
using Cheetah software (Neuralynx). Then each animal was
recorded for a 3-hour session: (1) 1 hour of baseline recording, (2)
at the end of the first hour, i.p. injection of a saline vehicle and
another hour of recording, (3) at the end of the second hour, i.p.
injection of 50 mg/kg ketamine and another hour of recording.
During the whole recording session, a 65 dB white-noise
background was played through speakers mounted on the
recording chamber and sporadic white-noise ‘‘clicks’’ 30 dB above
the background were administered. Animals were freely moving
and video-recorded by a camera mounted on the ceiling of the
recording chamber.
Recorded EEG signals were analyzed offline in Matlab using
the Chronux toolbox. Artifacts (extreme voltage values exceeding
1 mV) were discarded and power spectra and spectrograms were
generated using a multi-taper method. Position of the animal was
extracted from video recordings by using the Computer Vision
Systems Toolbox for Matlab.
Immunohistochemical Analysis
Adult mice were anesthetized with carbon dioxide, and
transcardially perfused with 2% PBS buffered paraformaldehyde.
Mouse brains were dissected out and further fixed in 4%
paraformaldehyde solution at 4uC for 24 hrs. After fixation, the
brains were dehydrated and embedded in paraffin. Serial, saggittal
sections of the brains were cut at 5 mm thickness, and then baked
at 60uC oven for one hour to firmly attach the sections to glass
slide. Immunohistochemical staining was conducted as described
[19,34]. Mouse monoclonal anti-GAD67 antibody (Sigma-Al-
drich, G5419) and anti-parvalbumin antibody (Sigma-Aldrich,
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p3088) were diluted with antibody diluents (Dako, S3022) at
1:60 K and 1:4000, respectively, as the primary antibodies for
overnight incubation at 4uC. ImmPRESS peroxidase-micropoly-
mer conjugated horse anti-mouse IgG (Vector Labs, MP-7402)
was used as the secondary antibody. Chromogenic reaction was
conducted with ImmPACT NovaRED Peroxidase Substrate
(Vector Labs, SK-4805). Slides were mounted with Cytoseal 60
mounting medium (Richard-Allan Scientific, 8310-16). For the
quantification of parvalbumin positive cells, Image J was used for
particle analysis with the parameters (particle size: 25 um-infinity;
circularity: 0.3–1.00). The threshold was adjusted to suppress the
background of individual slides, and counting accuracy was about
99% in overlay images. The GAD67 expression was quantified
with Image J using optical density. All images were first converted
into 8-bit grayscale images. Before the quantification, a calibration
of optical density was conducted for analysis of all images
according to the instructions (http://imagej.nih.gov/ij/docs/
examples/calibration/).
Western Blot
Proteins were extracted from mouse cortex and hippocampus,
and measured with Bradford (Abs 595 nm) method using
Coomassie Plus Protein Assay (Thermo Scientific, IL). After
electrophoresis, proteins were transferred onto PVDF membranes
which were subsequently blocked with 5% nonfat dry milk in
TBST buffer (pH 7.5, 10 mM Tris-HCl, 150 mM NaCl, and
0.1% Tween 20) at room temperature for 1 hour. The membranes
were incubated with the following primary antibodies at 4 ˚C
overnight: mouse monoclonal anti-GAD67 antibody (Sigma-
Aldrich, G5419) (1:10,000); sc-25270, mouse monoclonal anti-b-
Actin (1:5,000). After three times washing, the membranes were
further incubated with horseradish peroxidase (HRP)-conjugated
anti-mouse IgG (1:5,000, Cell signaling, MA) for 1.5 hour at room
temperature. Quantification of proteins expression was conducted
with Image J.
Statistical Analysis
For statistical analyses, repeated measures analysis of variance
(ANOVA) with genotypes as between-subjects factor and drug
treatment, block and prepulse intensity as within-subjects factors
were performed on the %PPI data and total distance traveled. Post
hoc analyses were carried out using Newman-Keuls or Tukey’s test.
Alpha level was set to 0.05. All statistical analyses were carried out
using the BMDP statistical software (Statistical Solutions Inc.,
Saugus, MA). For statistical analysis of parvalbumin and GAD67,
unpaired student’s t-test (significance level, 0.05) was used.
Supporting Information
Figure S1 Startle and startle habituation in Sp4 hypomorphic
mice injected with ketamine. Administration of ketamine de-
creased startle across all groups. No significant differences were
observed in startle responses between wildtype, heterozygous, and
Sp4 hyomorphic mice.
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